cobas p 612 pre-analytical system (LCP1) 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Roche Diagnostics 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2018-07-06
  • 사례 출판 날짜
    2018-07-06
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: roche diagnostics cobas p 612 pre-analytical system (lcp1) medical device manufacturer, roche diagnostics, has issued a medical device safety alert concerning its cobas p 612 pre-analytical system (lcp1) [gmmi: 07563116001, sw version: all versions from 2.0 and higher]. the manufacturer has confirmed that sample material may potentially come in contact with the pipetting nozzle during operation. the possible presence of biological material on the nozzle has the potential to cause contamination resulting in potential false positive results, depending on the sensitivity of the analytical technology. however, no complaints of false positives have been received from users. cobas p 612 (63x) (lcp1) systems that use disposable filter tips are not affected by a potential contamination as the filter tips create a physical barrier preventing liquid exposure to the nozzle. according to the manufacturer, the current issue deals with the occasional deposition of sample material at the bottom of the sample nozzle and its possible carry over to other specimens. in the case of molecular tests, even trace amount of nucleic acids may be amplified to detectable concentration and cause false positive results (e.G. hiv rna, hcv rna, hbv, and dna). this may lead to an incorrect diagnosis and inappropriate clinical management of the patient under examination. the root cause investigation is still ongoing. affected users using cobas p 612 pre-analytical systems (63x) for aliquoting in combination with non-filter tips must use filter tips until the root cause is identified and appropriate corrective actions have been implemented. affected users are reminded to perform the daily preparation and weekly device care procedures described in the operator’s manual. according to the local supplier, the affected product is distributed in hong kong. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 6 july 2018.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: Roche Diagnostics, cobas p 612 pre-analytical system (LCP1)
  • Manufacturer

Manufacturer